Medicinal Products

Dáil Éireann Debate, Wednesday - 22 January 2025

• Díospóireachtaí
• Aimsigh díospóireacht
  • Díospóireachtaí na Dála
  • Díospóireachtaí an tSeanaid
  • Díospóireachtaí Coiste
• Aimsigh vótáil
  • Vótálacha na Dála
  • Vótálacha an tSeanaid
  • Vótálacha Coiste
• Ceisteanna Parlaiminte
  • Ceisteanna scríofa
  • Ceisteanna ó bhéal
• Leideanna cuardaigh
• Nuair a bhíonn tionchar tromchúiseach ag aithrisí

Wednesday, 22 January 2025

Ceisteanna (1347)

Paul Murphy

Ceist:

1347. Deputy Paul Murphy asked the Minister for Health further to Parliamentary Question No. 1002 of 5 November 2024, given that Melatonin has not been reviewed since 2008, if he will instruct the NCPE to review and include this product for reimbursement under the Community Drugs Schemes; and if he will make a statement on the matter. [46423/24]

Freagraí scríofa

Minister for Health

Under the Health (Pricing and Supply of Medical Goods) Act 2013, the HSE has statutory responsibility for decisions on the pricing and reimbursement of medicines and devices; therefore, the matter has been referred to the HSE for attention and direct reply to the Deputy.

• An Freagra Roimhe Sin
• An Chéad Fhreagra eile